Virus and malignant lymphoma

doi:10.3760/cma.j.issn.1673-422X.2014.02.015

Abstract

Abstract: Virus infection is a major cause of lymphoma. Research shows that EpsteinBarr virus, human immunodeficiency virus, hepatitis C virus and hepatitis B virus involve in the occurrence and development of lymphoma through different ways and mechanisms. It is important significance that viral infection research elucidates the molecular mechanisms of lymphoma and explores therapy ways.

Key words: EpsteinBarr virus infections, HIV, Hepacivirus, Hepatitis B virus, Lymphoma

Wu Xia, Wang Yunsheng, Deng Fang. Virus and malignant lymphoma[J]. Journal of International Oncology, 2014, 41(2): 127-130.

References

［1］ Hjalgrim H, Engels EA. Infectious aetiology of Hodgkin and nonHodgkin lymphomas: a review of the epidemiological evidence［J］. J Intern Med, 2008, 264(6): 537-548. ［2］ Wu ZZ, Chow KP, Kuo TC, et al. Latent membrane protein 1 of EpsteinBarr virus sensitizes cancer cells to cisplatin by enhancing NFκB p50 homodimer formation and downregulating NAPA expression［J］. Biochem Pharmacol, 2011, 82(12): 1860-1872. ［3］ Lu J, Murakami M, Verma SC, et al. EpsteinBarr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBVpositive Blymphoma cells through upregulation of survivin［J］. Virology, 2011, 410(1): 64-75. ［4］ Muromoto R, Ikeda O, Okabe K, et al. EpsteinBarr virusderived EBNA2 regulates STAT3 activation［J］. Biochem Biophys Res Commun, 2009, 378(3): 439-443. ［5］ Staudt LM. Ⅱ. Therapy of DLBCL based on genomics［J］. Hematol Oncol, 2013, 1: 26-28. ［6］ Souza EM, Baiocchi OC, Zanichelli MA, et al. Impact of EpsteinBarr virus in the clinical evolution of patients with classical Hodgkin′s lymphoma in Brazil［J］. Hematol Oncol, 2010, 28(3): 137-141. ［7］ Lima RT, Seca H, Soares P, et al. EBV interferes with the sensitivity of Burkitt lymphoma Akata cells to etoposide［J］. J Cell Biochem, 2011, 112(1): 200-210. ［8］ Cheng W, Li YM, Yang DJ, et al. Effect of gossypol acetate on proliferation and apoptosis in Raji lymphoblastoid cell line［J］. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2009, 31(5): 527-532. ［9］ Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of EpsteinBarr virusDNA in plasma and peripheral blood mononuclear cells of extranodal NK/Tcell lymphoma, nasal type［J］. Blood, 2011, 118(23): 6018-6022. ［10］ Ian MX, Lan SZ, Cheng ZF, et al. Suppression of EBNA1 expression inhibits growth of EBVpositive NK/T cell lymphoma cells［J］. Cancer Biol Ther, 2008, 7(10): 1602-1606. ［11］ Omar H, Hgglund H, GustafssonJernberg A, et al. Targeted monitoring of patients at high risk of posttransplant lymphoproliferative disease by quantitative EpsteinBarr virus polymerase chain reaction［J］. Transpl Infect Dis, 2009, 11(5): 393-399. ［12］ Peric Z, Cahu X, Chevallier P, et al. Features of EpsteinBarr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation［J］. Leukemia, 2011, 25(6): 932-938. ［13］ Peric Z, Cahu X, Chevallier P, et al. Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation［J］. Bone Marrow Transplant, 2012, 47(2): 251-257. ［14］ Toulza F, Nosaka K, Takiguchi M, et al. FoxP3+ regulatory T cells are distinct from leukemia cells in HTLV1associated adult Tcell leukemia［J］. Int J Cancer, 2009, 125(10): 2375-2382. ［15］ Kozako T, Yoshimitsu M, Fujiwara H, et al. PD1/PDL1 expression in human Tcell leukemia virus type 1 carriers and adult Tcell leukemia/lymphoma patients［J］. Leukemia, 2009, 23(2): 375-382. ［16］ Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDSrelated lymphoma［J］. J Clin Oncol, 2010, 28(5): 773-779. ［17］ Wiggill TM, Mantina H, Willem P, et al. Changing pattern of lymphoma subgroups at a tertiary academic complex in a highprevalence HIV setting: a South African perspective［J］. J Acquir Immune Defic Syndr, 2011, 56(5): 460-466. ［18］ Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of nonAIDSdefining cancers in people with HIV infection［J］. J Clin Oncol, 2009, 27(6): 884-890. ［19］ Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early and lateHAART periods: the Swiss HIV Cohort Study［J］. Br J Cancer, 2010, 103(3): 416-422. ［20］ Kreuzaler M, Rauch M, Salzer U, et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors［J］. J Immunol, 2012, 188(1): 497-503. ［21］ Tussiwand R, Rauch M, Flück LA, et al. BAFFR expression correlates with positive selection of immature B cells［J］. Eur J Immunol, 2012, 42(1): 206-216. ［22］ Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferonalpha, ribavirin, and rituximab combined therapy of hepatitis C virusrelated mixed cryoglobulinemia: a longterm study［J］. Blood, 2010, 116(3): 343-353. ［23］ Mazzaro C, Monti G, Saccardo F, et al. Efficacy and safety of peginterferon alfa2b plus ribavirin for HCVpositive mixed cryoglobulinemia: a multicentre openlabel study［J］. Clin Exp Rheumatol, 2011, 29(6): 933-941. ［24］ HartridgeLambert SK, Stein EM, Markowitz AJ, et al. Hepatitis C and nonHodgkin lymphoma: the clinical perspective［J］. Hepatology, 2012, 55(2): 634-641. ［25］ Charles ED, Brunetti C, Marukian S, et al. Clonal B cells in patients with hepatitis C virusassociated mixed cryoglobulinemia contain an expanded anergic CD21low Bcell subset［J］. Blood, 2011, 117(20): 5425-5437. ［26］ Martyak LA, Yeganeh M, Saab S. Hepatitis C and lymphoproliferative disorders: from mixed cryoglobulinemia to nonHodgkin′s lymphoma［J］. Clinl Gastroenterol Hepatol, 2009, 7(8): 900-905. ［27］ Becker N, Fortuny J, Alvaro T, et al. Medical history and risk of lymphoma: results of a European casecontrol study (EPILYMPH)［J］. J Cancer Res Clin Oncol, 2009, 135(8): 1099-1107. ［28］ Marcucci F, Mele A. Hepatitis viruses and nonHodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities［J］. Blood, 2011, 117(6): 1792-1798. ［29］ Nath A, Agarwal R, Malhotra P, et al. Prevalence of hepatitis B virus infection in nonHodgkin lymphoma: a systematic review and metaanalysis［J］. Intern Med J, 2010, 40(9): 633-641. ［30］ Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of nonHodgkin lymphoma in South Korea: a cohort study［J］. Lancet Oncol, 2010, 11(9): 827-834. ［31］ Chen MH, Hsiao LT, Chiou TJ, et al. High prevalence of occult hepatitis B virus infection in patients with B cell nonHodgkin′s lymphoma［J］. Ann Hematol, 2008, 87(6): 475-480.

[1]	Yin Yunyan, Li Hui, Li Yuchen, Hui Hui, Xu Jingyan. Clinical application of histone deacetylase inhibitors in non-Hodgkin lymphoma [J]. Journal of International Oncology, 2022, 49(8): 499-504.
[2]	Wang Liuxue, Xi Xiaoping, Liu Jingjing, Shen Guomin, Yang Haiping. Research progress of metformin in non-Hodgkin lymphoma [J]. Journal of International Oncology, 2022, 49(7): 436-440.
[3]	Guo Yiwei, Liu Aichun. Treatment of EB virus positive diffuse large B cell lymphoma [J]. Journal of International Oncology, 2021, 48(7): 385-388.
[4]	Li Qiao'er, Zou Liqun. Stratified therapeutic choices in elderly patients with diffuse large B-cell lymphoma [J]. Journal of International Oncology, 2021, 48(5): 317-320.
[5]	Qiao Wei, Song Teng, Chen Xinrui, Wang Huaqing. Effect of excessive activation of PI3K signaling pathway on the prognosis of patients with non-Hodgkin lymphoma and the efficacy of targeted drugs [J]. Journal of International Oncology, 2021, 48(2): 121-124.
[6]	Chen Lina, Guo Zhi, Liu Xuanyong, Chen Xiao, Zhang Yihuizhi, Li Xumian, Wei Liya, Wang Yueqiao, Xie Jing. Application study of EAC mobilization scheme in autologous hematopoietic stem cell transplantation of lymphoma [J]. Journal of International Oncology, 2021, 48(11): 666-672.
[7]	Xu Lei, Dai Jing, Zhang Qian, Zhang Wenli, Li Jinmeng, Zhang Hongyu. Clinical analysis of 93 cases of adult patients with acute lymphoblastic leukemia [J]. Journal of International Oncology, 2020, 47(9): 535-541.
[8]	Yang Lei, Zhang Chuanyu, Zhang Zaixian, Liu Huan. Radiogenomics in non-small cell lung cancer [J]. Journal of International Oncology, 2020, 47(9): 555-559.
[9]	Zhao Ke, Wang Huaqing. Progress of new drugs on relapsed/refractory peripheral T-cell lymphoma [J]. Journal of International Oncology, 2020, 47(6): 321-326.
[10]	Qi Fei, Dong Mei. Clinical characteristics and survival analysis of extra-upper aerodigestive tract extranodal NK/T-cell lymphoma [J]. Journal of International Oncology, 2020, 47(3): 157-163.
[11]	Chai Yue, Dong Mei. Prognostic role and mechanisms of abnormal coagulation system in lymphoma [J]. Journal of International Oncology, 2020, 47(10): 637-640.
[12]	Guo Jianlin, Zhang Chuanyu, Yu Hualong, Zhang Zaixian. Progress of radiogenomics in lung cancer [J]. Journal of International Oncology, 2019, 46(9): 544-547.
[13]	Chen Wenjun, Wang Junjuan, Qi Jianni, Dong Chonghai, Qin Chengyong. Advancement of the risk prediction of hepatocellular carcinoma in patients with chronic hepatitis B virus infection [J]. Journal of International Oncology, 2019, 46(9): 558-561.
[14]	Sun Ye, Sheng Lixia, Ouyang Guifang. MicroRNAs and diffuse large B cell lymphoma [J]. Journal of International Oncology, 2019, 46(9): 566-569.
[15]	Xiang Mingyue, Wang Lili, Han Dali. Progress of treatment for primary mediastinal B-cell lymphoma [J]. Journal of International Oncology, 2019, 46(8): 505-508.